Advance your breakthrough treatments with a global lung cancer CRO
Lung cancer is devastating for patients and their families, but treatments like yours offer hope. We’re committed to helping you bring that hope to the patients who need it through cutting-edge science.
Our lung cancer specialists support the whole range of clinical studies, from first in human and early phase to Phase III (registrational studies) and on through post-approval trials. As a proven lung cancer CRO, we have wide experience as medical leads in different indications (adjuvant, neoadjuvant, chemo-radiation, and in metastatic settings) and with different investigational compounds, including:
- Small molecule inhibitors
- Monoclonal antibodies
- Viral vectors
- Chemotherapy
- Immunotherapy
- Antibody drug conjugates (ADCs)
- Bispecific antibodies and derivatives
- Combination therapies
Experience in the past 5 years in lung cancer
+
clinical projects
+
patients
+
sites
Global presence
Our teams are based in Europe, North America, and the APAC region, providing a global presence for high-quality medical oversight and monitoring. Our presence in APAC is particularly strong, with 8,800+ staff and 20+ offices across the region, including Japan. We’re experienced in managing large studies across these regions, and have successfully delivered global registrational studies in lung cancer.
Advanced patient recruitment
Competition for patient enrollment is a common challenge, but as a proven lung cancer CRO, we have the experience and tools to recruit the sites and patients you need. We use real-world data, AI-driven feasibility models, and our strong relationships with sites and advocacy groups to not only find the right sites and investigators but get the word out to patient populations about new opportunities.
Regulatory experience
Our team of 1,000+ global regulatory experts has experience with many authorities around the world, including FDA, EMA, MCC, MHRA, PMDA, BfArM, NPMA, and PEI. That expertise allows us to navigate regulatory and market access hurdles across regions — charting the clearest course to approval.
Experience with small cell lung cancer
Studies involving small cell lung cancer come with unique challenges, particularly surrounding patient recruitment and retention due to the aggressiveness of the disease. Our oncology CRO team, however, has successfully delivered multiple large, global studies, with one of the compounds now approved in Europe.